JERSEY CITY, N.J., Dec. 4, 2015 /PRNewswire/ -- Aoxing
Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"), a
specialty pharmaceutical company focusing on research, development,
manufacturing, and distribution of narcotic, pain-management, and
addiction treatment pharmaceuticals, today announced the
inauguration of its new Narcotic and Psychotropic Drug Research
Center. Construction of the Center was funded by the Reform and
Development Commission of Hebei
Province in China along
with Aoxing Pharma's Chinese subsidiary, with a total investment of
US$2.15 million.
This state-of-the art Research Center occupies
2200m2, and meets current GLP and GMP standards.
The Center will provide facilities for narcotic and psychotropic
drug research and development, including chemical synthesis,
transdermal patch formulation, pilot manufacturing, quality review
and analytical labs. The Center is outfitted with the latest
technology, to offer an optimal research environment to the
research scientists at Aoxing Pharma.
"We are delighted by the inauguration of the new R&D Center,
and are honored to receive this powerful endorsement by the Chinese
government," said Mr. Zhenjiang Yue,
the Chairman and CEO of Aoxing Pharma. "The government contributed
to the funding of this project in recognition of our company's
strong commitment to the narcotic drug and psychiatric treatment
business. Government endorsement of our efforts can also be
seen in our recent receipt of authorization from the China
FDA (CFDA) to initiate four drug programs, including Lorcaserin
Hydrochloride tablets and Lorcaserin Hydrochloride API (active
pharmaceutical ingredient), weight-reduction drugs for overweight
and obese patients, as well as Caffeine tablets (for swallowing)
and Caffeine buccal tablets (for dissolving in the mouth), for the
management of mental fatigue and headache. With government
approval and our new government-funded research facility, we are
well positioned to quickly introduce such products into the Chinese
pharmaceutical market."
About Aoxing Pharmaceutical Company, Inc.
Aoxing Pharmaceutical Company, Inc. is a US incorporated
specialty pharmaceutical company with its operations in
China, specializing in research,
development, manufacturing and distribution of a variety of
narcotics and pain-management products. Headquartered in
Shijiazhuang City, outside
Beijing, Aoxing Pharma has the
largest and most advanced manufacturing facility in China for highly regulated narcotic medicines.
Its facility is one of the few GMP facilities licensed for the
manufacture of narcotic medicines by the China Food and Drug
Administration ("CFDA"). For more information, please visit:
www.aoxingpharma.com.
Safe Harbor Statement from Aoxing Pharmaceutical Company,
Inc.
Certain statements made in this press release are
forward-looking and are made pursuant to the safe harbor provisions
of the Securities Litigation Reform Act of 1995. Such statements
involve risks and uncertainties that may cause actual results to
differ materially from those set forth in these statements. All
forward-looking statements included herein are based upon
information available to the Company as of the date hereof and,
except as is expressly required by the federal securities laws, the
Company undertakes no obligation to update or revise any
forward-looking statements, whether as a result of new information,
changed circumstances or future events or for any other reason. To
the extent that any statements made here are not historical, these
statements are essentially forward-looking. Undue reliance should
not be placed on forward-looking information. The economic,
competitive, governmental, technological and other risk factors
identified in the Company's filings with the Securities and
Exchange Commission, specifically, Item 1A, "Risk Factors," in the
Form 10-K for the year ended June 30,
2015, may cause actual results or events to differ
materially from those described in the forward looking statements
in this press release. The Company undertakes no obligation to
publicly update or revise any forward-looking statements, whether
because of new information, future events, or otherwise.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/aoxing-pharma-announces-opening-of-government-funded-drug-research-center-300188105.html
SOURCE Aoxing Pharmaceutical Company, Inc.